Akari Therapeutics, Plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akari Therapeutics, Plc
Promising pivotal data boost chances for Omeros’ narsoplimab to become a highly needed, first-to-market drug for the treatment of a deadly complication of stem cell transplants.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
The latest drug development news and highlights from our US FDA Performance Tracker.
The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.
- Other Names / Subsidiaries
- Celsus Therapeutics plc
- Morria Biopharmaceuticals, plc
- Volution Immuno Pharmaceuticals SA